Monash Ivf Group
Monash IVF Group is a provider of assisted reproductive services (ART) and ultrasound services. The company focuses on developing assisted reproductive technologies and tertiary level prenatal diagnostics. They operate clinics and provide related services to patients seeking fertility treatments.
Short position
Monash Ivf Group (ASX:MVF) has 1.06% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,126,817 shares. Over the past 30 days that figure has fallen 0.47 percentage points, and over 90 days it has fallen 0.58 percentage points. Its highest recorded short interest was 7.53% in September 2025. MVF is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Monash Ivf Group (MVF) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $269.5MM (source: ASX (Markit))vs $271.9MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- $7.4MM (source: ASX (Markit))vs $25.0MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (diluted)
- $0.019T (source: Derived: trailing 12 months at year end)vs $0.064T (source: Derived: trailing 12 months at year end) (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- −0.9%FY
- EPS YoY
- −70.3%TTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of MVF FY26 Appendix 4E and Financial Report, 31 Aug 2026
Monash IVF Group's revenue fell 0.9% to $269.5m and statutory net profit plunged 67.6% to $8.3m for FY2026. A final dividend of 1.3 cents per share was declared, bringing the full-year dividend to 2.5 cents. Underlying NPAT of $16.1m missed the company's guidance of $17m-$18m, reflecting a softer domestic market and cost pressures.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- 88.6%
- Operating margin
- 7.5%
- Net margin
- 2.8%
- FCF margin
- 4.8%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- 1.74×
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- 3.2×
- Cash dividends paid / net profit
- 72.8%
- Market cap
- n/a (no share count we can vouch for)
- P/E
- 39.2×
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $269.5MM (source: ASX (Markit)) | $271.9MM (source: ASX (Markit)) | $255.0M | $213.6M |
| Gross profit | $238.7MT (source: Derived: trailing 12 months at year end) | n/a | $228.4M | $191.2M |
| Operating income | $20.2MT (source: Derived: trailing 12 months at year end) | n/a | −$5.6M | $33.1M |
| EBITDA | $41.0MT (source: Derived: trailing 12 months at year end) | n/a | $10.8M | $46.4M |
| EBIT | $17.7MT (source: Derived: trailing 12 months at year end) | n/a | −$7.8M | $31.1M |
| Interest expense | $6.3MT (source: Derived: trailing 12 months at year end) | n/a | $2.9M | $1.2M |
| Pretax income | $11.4MT (source: Derived: trailing 12 months at year end) | n/a | −$10.7M | $29.8M |
| Tax | $3.1MT (source: Derived: trailing 12 months at year end) | n/a | −$4.7M | $7.9M |
| NPAT | $7.4MM (source: ASX (Markit)) | $25.0MM (source: ASX (Markit)) | −$6.5M | $21.8M |
| Net interest income | −$8.8MT (source: Derived: trailing 12 months at year end) | n/a | −$5.3M | −$3.3M |
| EPS basic | $0.019T (source: Derived: trailing 12 months at year end) | $0.064T (source: Derived: trailing 12 months at year end) | −$0.017 | $0.056 |
| EPS diluted | $0.019T (source: Derived: trailing 12 months at year end) | $0.064T (source: Derived: trailing 12 months at year end) | −$0.017 | $0.056 |
| Shares | n/a | n/a | 389.6M | 389.6M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- MVF FY26 Appendix 4E and Financial ReportAnnual Results31 Aug 2026via asx_announcements
- 1H26 Appendix 4D and Financial ReportHalf Year Results26 Feb 2026via asx_announcements
- FY26 Half Year Results ReleaseHalf Year Results25 Feb 2026via asx_announcements
- Monash IVF Group 2025 Annual ReportAnnual Report31 Dec 2025via crawler
- Monash IVF Group 2025 Notice of MeetingFinancial Report31 Dec 2025via crawler
- Investor presentation for Full Year FY2025Investor Presentation31 Dec 2025via crawler
- FY2025 Annual Report to ShareholdersAnnual Report20 Oct 2025via asx_announcements
- MVF FY25 Appendix 4E and Financial ReportAnnual Results22 Aug 2025via asx_announcements
- 1H25 Appendix 4D and Financial ReportHalf Year Results27 Feb 2025via asx_announcements
- Monash IVF Group 2024 Annual ReportAnnual Report31 Dec 2024via crawler
Showing 10 of 19 reports